NCIt definition : A human bispecific antibody, with potential antineoplastic activity. Rezetamig contains
two binding sites, one for the tumor-associated antigen (TAA) CD22, and one for the
T-cell surface antigen CD3. Upon administration, rezetamig binds to both CD3 on T-cells
and CD22-expressing B-lineage tumor cells. The resulting cross-linkage may trigger
a potent cytotoxic T-lymphocyte (CTL) response against the CD22-expressing tumor B-cells.
CD22 is exclusively expressed on B-cells and is often overexpressed in B-lymphocytic
malignancies. It negatively regulates the B-cell receptor.;
Semantic type(s)